期刊文献+

P_(BAD)表达系统对抗-HBs Fab抗体表达的影响 被引量:1

Effects of P_(BAD)expression system on anti-HBs Fab expression
下载PDF
导出
摘要 目的 研究PBAD 替换Plac的原核表达系统对重组抗 HBsFabs的表达效率、产量及其抗体活性的影响。方法 通过Westernblot、抗体不同稀释度的Dotblot和抗原特异性结合实验 ,对两种表达系统进行比较。结果 在PBAD控制下表达的抗 HBsFabs与Plac控制下的相比 ,Westernblot显示两种表达系统都能完整表达抗 HBsFab抗体 ,Mr 为 5 0 0 0 0。PBAD表达系统表达的抗 HBsFabs多以可溶形式存在于周质腔中 ,而Plac表达系统表达的抗 HBsFabs更多的释放入培养上清液。抗体不同稀释度的Dotblot结果显示pBAD 抗HBsFab表达系统表达的抗体效价较pComb3 抗HBsFab高 ,乙型肝炎表面抗原特异性结合实验证实两种表达系统表达的抗体的抗原结合活性无明显差别。结论 PBAD表达系统明显提高了抗 Objective To investigate the effects of P BAD, as an alternative system to P lac, on the expression efficiency, expression production, and antigen-binding activity of the recombinant anti-HBs Fab. Methods The two prokaryotic expression systems were compared by Western blotting and dot blotting with different dilution activities. Results The human recombinant anti HBs Fabs were completely expressed by the two prokaryotic expression systems. The molecular weight of Fab was about M r 50 000 and the protein was confirmed to be anti-HBs Fab by Western blotting. The anti-HBs Fabs expressed by P BAD were localized to the soluble periplasmic fraction whereas P lac expressed anti-HBs Fabs were released into the culture supernatant. Dot blotting with different dilution of Fab indicateed that the title of Fab from P BAD expression system was higher than that from pComb3. No significant difference of anti-HBs Fab binding capacity between the two systems was found. Conclusion P BAD expression system elevates the Fab production, and maintains the original antibody activity.
出处 《免疫学杂志》 CAS CSCD 北大核心 2005年第1期66-68,共3页 Immunological Journal
关键词 抗HBsAg抗体 蛋白表达 WESTERN BLOT Anti-HBsAg antibody Protein expression Western blot
  • 相关文献

参考文献8

  • 1韩焕兴,孔宪涛.人源抗HBsAg单克隆抗体组合文库的建立[J].中国免疫学杂志,1996,12(5):299-302. 被引量:7
  • 2陈竞华,王琰,刘群英,王雅明,徐建军,刘华.人源性噬菌体抗体库的构建及HBsAg人单抗的筛选[J].中华微生物学和免疫学杂志,1995,15(3):158-162. 被引量:56
  • 3陆慧琦,韩焕兴,叶伟民,杨丹榕.κ、λ轻链C区基因的克隆与表达[J].免疫学杂志,2003,19(5):394-396. 被引量:1
  • 4Zebedee SL, Barbas CF,Hom YL, et al. Human combinatorial antibody libraries to hepatitis B surface antigen[J]. Proc Nail Acad Sci USA, 1992,89(8):3 175- 3179.
  • 5Pluckthun A, Antibody engineering: advances from the use of Escherichia coli expression systems [ J ]. Biotechnology (NY), 1991, 9 (6): 545-551.
  • 6Clark MA, Hammond FR, Papaioannou A, et al. Regulation and expression of human Fabs under the control of the Escherichia coli arabinose promoter, PBAD [ J ]. Immunotechnology, 1997, 3 (3): 217 - 226.
  • 7Better M, Chang CP, Robinson RR, et al. Escherichia coli secretion of an active chimeric antibody fragment [ J ]. Science, 1988, 240 (4 855): 1 041 - 1 043.
  • 8Guzman LM, Belin D, Carson MJ, et al. Tight regulation,modulation, and high-level expression by vectors containing the arabinose PBAD promoter [ J ]. J Bacteriol, 1995,177 (14): 4 121-4 130.?A

二级参考文献8

共引文献61

同被引文献9

  • 1陆慧琦,韩焕兴,安峰,叶伟民,曾万杰,薛菖.人源抗-HBs轻链与干扰素-α融合蛋白的克隆及表达[J].中华传染病杂志,2005,23(4):229-232. 被引量:1
  • 2Akman SA, Okcu SC, Halicioglu O, et al. Therapeutic efficacy of sequential and simultaneous treatments with interferon-a and larnivudine in children with chronic hepatitis B[J]. Pediatr lnt, 2007, 49 (6) : 848-852.
  • 3Fung J, Lai CL, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B[J]. Expert Rev Anti Infect Ther, 2010, 8(6): 717-726.
  • 4Asif-Ullah M, Choi KJ, Choi KI, et al. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus[J]. Antiviral Res, 2006, 70(2): 85-90.
  • 5Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B[J]. J Viral Hepat, 2010, 17(9): 601-610.
  • 6Hansen BE, Buster EH, Steyerberg EW, etal. Prediction of the re sponse to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment[J]. J Med Virol, 2010, 82(7): 1135-1142.
  • 7Satin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients[J].Am J Gastroenterol, 2005, 100(11) : 2463-2471.
  • 8Hong SH, Cho O, Kim K, etal. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells[J]. Virus Res, 2007, 126(1/2) : 245-249.
  • 9Wesolowski J, Alzogaray V, Reyelt J, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity[J]. Med Microbiol Immunol, 2009, 198(3): 157-174.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部